相关实验视频

Updated: Jun 27, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

简氏激酶抑制剂作为耐火内源性非传染性尿道炎的第三线治疗方法

Justus G Garweg^1,2, Kim A Straessle¹

¹Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland.

Ocular immunology and inflammation

|May 6, 2024

概括

氏激酶 (JAK) 抑制剂在非传染性脑膜炎 (NIU) 中表现有前途,但需要更多的安全性数据. 这些口服JAK抑制剂可能为耐火NIU病例提供生物药物的替代品.

科学领域:

眼科医生眼科眼科
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

非传染性脑膜炎 (NIU) 是一种影响眼睛的免疫媒介炎症状况.
生物疗法用于耐火NIU,但正在探索替代方案.
简氏激酶 (JAK) 抑制剂代表了一类新的免疫调节剂.

研究的目的:

审查关于用于耐火性非传染性脑膜炎 (NIU) 患者的Janus激酶 (JAK) 抑制剂的现有证据.
在NIU治疗的背景下更新对JAK抑制剂有效性和安全性的理解.

主要方法:

在PubMed,Scopus和CENTRAL数据库中进行了全面的文献搜索,截至2023年10月.
关键词包括"非传染性脑膜炎"和"Janus激酶抑制剂"或"JAK抑制剂".
文章的选择基于临床相关性,眼病重点,出版日期,研究设计和安全性评估.

主要成果:

简氏激酶 (JAKs) 是参与免疫反应的信号蛋白;它们的抑制在像NIU这样的免疫媒介疾病中具有治疗潜力.
雅克抑制剂向多种细胞因子,提供与生物药物不同的机制,可以口服.
虽然建议有效性,但NIU中JAK抑制剂的安全性数据目前令人困惑和矛盾,缺乏针对炎症性眼病的具体信息.

结论:

由于缺乏受控临床试验,NIU的JAK抑制剂治疗被认为是实验性的.
这些药物可能是为危及视力的NIU或对常规或生物疗法的反应不足的病例保留的.
在NIU的治疗算法中,JAK抑制剂的最终作用尚未确定,等待进一步的安全性和有效性数据.

关键词:

简氏酶抑制剂简氏酶抑制剂这是一种TNF-α抑制剂.非传染性紫外线炎.在安全方面,安全是安全的.小分子的小分子.

更多相关视频

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...